CATO 佳途 · CNAS + ANAB ISO 17034 双体系认可标准物质生产者
销售顾问Sales contact 卢振明+86 185 2048 1969kaka@cato-chem.com
Analytical Methods

Nicotinamide: Three Compounds With One Formula, and the Nitrile That Never Hydrolyzed

Most impurity profiles are stories about time. Nicotinamide↗ is a story about selectivity: four of its first five lettered impurities are one reaction step away from the drug substance, and three of them weigh exactly the same as the parent. That combination makes the molecule a good test of whether a method is specific or merely precise.

Note: product names shown in red (marked with ↗) are links - click through to the product page for structure, CAS number, purity and lead time.

2026-11-04 · Updated 2026-11-04 · Guangzhou CATO Technology Co., Ltd.

A vitamin whose impurity list is a selectivity map

Key points

  1. Nicotinamide is C6H6N2O, 122.12, CAS 98-92-0. Three separate compendial impurities in this catalogue share that exact formula: the parent, picolinamide and isonicotinamide.
  2. The amide sits between two neighbors in the same reaction sequence. Incomplete hydration leaves 3-cyanopyridine, C6H4N2; over-hydrolysis gives nicotinic acid, C6H5NO2. Both are catalogued and both are measurable in the same run.
  3. At a 500 mg daily dose the identification threshold stays at 0.10 percent rather than dropping to an absolute limit, because 1.0 mg/day corresponds to 0.20 percent[1].
  4. None of the three isobars can be identified by mass or by ultraviolet spectrum alone. Retention, and only retention, separates them, so every peak needs its own standard.

Most impurity profiles are stories about time: a molecule degrades, a peak grows, a shelf life shortens. Nicotinamide is not one of those. Its profile is a story about selectivity, because every significant impurity is a compound the synthesis could plausibly have made and did not quite. This catalogue carries 284 nicotinamide entries, and among the first five lettered impurities, four are one reaction step away from the drug substance.

Nicotinamide, CAS 98-92-0: pyridine-3-carboxamide, the amide that sits between a nitrile and an acid
Nicotinamide, CAS 98-92-0: pyridine-3-carboxamide, the amide that sits between a nitrile and an acid

The industrial route explains the pattern. 3-Methylpyridine is ammoxidation-oxidized to 3-cyanopyridine, and the nitrile is then partially hydrated to the amide, usually over a manganese dioxide or copper-based catalyst. Partial hydration is the operative word: stop too early and the nitrile survives, go too far and the amide hydrolyzes to the carboxylic acid. A plant therefore controls the reaction by conversion rather than by purification, and the impurity profile at release is a record of where that conversion landed.

The dose context is mild compared with most of this catalogue. Nicotinamide tablets are commonly 50 or 100 mg, with high-dose regimens reaching 500 mg a day, so the identification threshold is set by percentage rather than by absolute mass: 1.0 mg/day at 500 mg/day equals 0.20 percent, well above the 0.10 percent default[1]. The percentage limits mean that a 0.08 percent nitrile is a reportable but unidentified peak, which is precisely the situation where a laboratory reaches for a reference standard it does not have.

Impurity B: the nitrile that never hydrolyzed

3-Cyanopyridine, CAS 100-54-9, is EP impurity B. It is the smallest possible marker of an incomplete reaction, and it has one property that makes it analytically awkward: it is far more lipophilic than the amide it precedes. On a C18 column with a water-acetonitrile gradient, the nitrile elutes well after the parent, in a region where nothing else of interest sits, which is convenient. On a polar-embedded or HILIC column run for the isobars, it moves to the other end of the chromatogram. Method transfer between the two platforms therefore requires re-identification, not just re-validation.

3-Cyanopyridine, CAS 100-54-9, EP impurity B: the unhydrolyzed nitrile precursor
3-Cyanopyridine, CAS 100-54-9, EP impurity B: the unhydrolyzed nitrile precursor

What makes the nitrile interesting is not its toxicity, which is unremarkable for an aromatic nitrile, but its evidentiary value. A batch with 0.02 percent nitrile and 0.01 percent acid has been run to a conversion that favors the amide; a batch with 0.15 percent nitrile and no acid has been stopped early and purified afterwards. The ratio of the two tells a reviewer more about the process than either number alone, and it is the sort of argument that belongs in section 3.2.S.3.2 rather than in a specification.

The acid on the other side, and why the boundary is blurry

Nicotinic acid, C6H5NO2, CAS 59-67-6, is both a process impurity and a degradation product, and this is the one place in the molecule where the two cannot be separated by context alone. It is formed in the reactor when hydration overshoots, and it is formed in the tablet when residual moisture and an acidic excipient meet the amide over eighteen months. This catalogue carries it as a separate variety with 103 entries, which is a hint about how much analytical work the compound attracts in its own right.

Separating the two contributions is a spiking question, not a chromatographic one. Add nicotinic acid to placebo at the specification level, store it under accelerated conditions, and see whether the spiked amount stays put. If it does, the acid in the drug product is process-derived; if it grows, hydrolysis is running in the package and the specification needs a degradation-based justification rather than a batch-history one. The same experiment settles whether the limit should be tightened for a hygroscopic formulation.

Impurities C and D: two isomers that should not be there

Picolinamide, CAS 1452-77-3, is EP impurity C, and isonicotinamide, CAS 1453-82-3, is EP impurity D. Both are pyridinecarboxamides with the amide at the wrong ring position, and neither can form from nicotinamide by any rearrangement available in a tablet. They enter through the feedstock. Commercial 3-methylpyridine carries 2- and 4-picoline at low levels, ammoxidation converts all three to the corresponding nitriles, and hydration is not selective enough to reject them.

Isonicotinamide, CAS 1453-82-3, EP impurity D: the para isomer of the drug substance
Isonicotinamide, CAS 1453-82-3, EP impurity D: the para isomer of the drug substance
Picolinamide, CAS 1452-77-3, EP impurity C: the ortho isomer, capable of intramolecular hydrogen bonding
Picolinamide, CAS 1452-77-3, EP impurity C: the ortho isomer, capable of intramolecular hydrogen bonding

The two behave differently on a column, and the difference is worth knowing before method development starts. The para isomer is symmetrical and behaves almost exactly like the parent, which is why it is the harder of the two to resolve. The ortho isomer can form an intramolecular hydrogen bond between the amide N-H and the pyridine nitrogen, which changes its solvation, its retention and its peak shape, and which also makes it the one that responds most strongly to mobile phase pH, and to the metal surfaces it meets in the injector and the column frit[2]. A method developed at pH 3 may resolve the ortho isomer and merge the para one; a method at pH 6.5 may do the reverse.

EntryCASFormulaRelationshipOrigin
EP impurity B100-54-9C6H4N2nitrile precursor, two hydrogens fewerincomplete hydration
EP impurity C1452-77-3C6H6N2Oortho isomer, same formula2-picoline in the feedstock
EP impurity D1453-82-3C6H6N2Opara isomer, same formula4-picoline in the feedstock
EP impurity E1986-81-8C6H6N2O2pyridine N-oxide, one oxygen moreoxidation
nicotinic acid59-67-6C6H5NO2amide hydrolyzed to acidover-hydrolysis, and hydrolysis on storage

Table note: letters as catalogued; formulas are the primary identifiers, because three entries share one formula.

Separating three compounds that weigh the same

Nicotinamide, picolinamide and isonicotinamide are isobaric at 122.12 and share a chromophore, so both of the shortcuts analysts rely on are closed. Mass spectrometry returns one number for three structures unless the experiment is MS/MS with a difference in fragmentation, and even then the fragments are similar because the molecules differ only in where the amide sits. Photodiode array returns three nearly superimposable spectra, so peak purity across the main peak is not evidence of anything.

That leaves selectivity, and the practical consequence is that each of the three needs its own reference standard before a method can be called specific. Retention time alone is a weak claim: picolinamide and nicotinamide can swap elution order between a C18 and a phenyl-hexyl phase, and the switch has been observed on the same chemistry from different manufacturers because residual silanols differ. A defensible method document shows the three standards injected individually, then mixed, then spiked into a batch, with resolution reported for both critical pairs[3].

Two further details cost people time. Nicotinamide is polar enough that on a plain C18 column with a high aqueous start it elutes close to the void, where the injection solvent and the buffer salts live, so a sample diluent that differs from the mobile phase will distort the early region. And nicotinamide N-oxide, CAS 1986-81-8, is more polar still and will elute before the parent on every reversed-phase system, which means it is the first peak in the chromatogram and the easiest one to lose in the solvent front.

What the filing has to show

Chinese registration activity for nicotinamide is modest and recent, weighted toward new drug applications and supplementary filings rather than generic copies, which changes what a reviewer looks at.

Nicotinamide: CDE accepted filings and applicants
Accepted filings: 37; applicants involved: 30 (aggregated from CDE public acceptance records).
By application type: new drug 17, supplementary application 14, import re-registration 3, generic 3.
By year: 2001: 1, 2002: 1, 2003: 5, 2005: 4, 2007: 1, 2011: 2, 2013: 2, 2015: 1, 2017: 1, 2020: 1, 2022: 2, 2023: 5, 2024: 5, 2025: 2, 2026: 4.
Source: Center for Drug Evaluation (CDE), NMPA, public acceptance records; retrieved 2026-11-04 02:25:23; counts are acceptance records, not approvals.

The questions that matter are narrow. First, specificity for the two ring isomers: how were the peaks assigned, and is there a standard for each? Second, the origin argument for nicotinic acid: is it process or degradation, and what experiment supports the claim? Third, the N-oxide, which is the only entry in the list that is unambiguously oxidative and therefore the one that links the impurity profile to the packaging and the antioxidant strategy. A filing that answers those three, with spiked recovery data and individual standards, tends not to attract a second round on impurities. Each of the lettered entries discussed here has a monograph entry in the Chinese Pharmacopoeia[4].

Where the family comparison misleads

Three pyridine derivatives sit near nicotinamide in this catalogue and each invites an analogy that does not hold. Nicotinic acid is the hydrolysis product, not a sibling API, and its own impurity profile is dominated by different chemistry. Isoniazid is a hydrazide rather than an amide: hydrolyze it and you release hydrazine, which is a genotoxicant, so the stability question there is a toxicological one and not a question of two isobaric peaks. Nikethamide is the N,N-diethyl amide, with no N-H to hydrogen bond and no capacity to form the same dimer, so its chromatography and its impurity map transfer poorly. Pyridoxine is the closest analogue in the catalogue by ring alone: it is a pyridine too, but its three hydroxyls and its own photochemistry dominate everything, and no amide-based reasoning carries across.

The only genuine family statement is about the ring. Any pyridine-3-carboxamide will carry positional isomers if the feedstock does, and any of them will be isobaric with its parent. That is a property of the scaffold, not of the drug, and it is the reason the isomer standards are worth holding even for a product with a modest impurity list.

Three practical traps

Integrating the N-oxide as part of the solvent front is the first; it elutes before the parent on every reversed-phase system, and a gradient that starts at 95 percent aqueous pushes it into the injection peak. Reporting a single unknown at relative retention 0.92 without a standard is the second; in practice that peak is usually the para isomer, and calling it unknown invites a question that a 40 mg standard would have prevented. The third is method transfer between a C18 and a mixed-mode column without re-running the isomer mix, which is how a validated method silently loses specificity for the pair it was validated on.

This catalogue carries 284 nicotinamide entries, including 3-cyanopyridine, picolinamide, isonicotinamide, the N-oxide and the deuterated analogues used as internal standards: nicotinamide reference standards.

Frequently Asked Questions

Are picolinamide and isonicotinamide really impurities of nicotinamide, or just related compounds?
They are genuine compendial impurities, lettered C and D, and they enter through the feedstock rather than through any reaction of nicotinamide itself. Commercial 3-methylpyridine contains 2- and 4-picoline, and the ammoxidation-hydration sequence carries all three isomers through to the amide.
Can the three isobars be distinguished by LC-MS/MS?
Only partly. All three give the same precursor at 123.06 for the protonated ion, and the fragments differ mainly in relative abundance rather than in identity. A method that relies on MS/MS ratios for assignment is fragile; a chromatographic separation with individual standards is not.
Which is the better marker of process control, the nitrile or the acid?
The ratio of the two. A high nitrile with low acid means the hydration was stopped early; the reverse means it overshot. Neither number on its own tells a reviewer where the conversion landed, and the pair does.
Why does nicotinamide elute so close to the void?
It is small, polar and uncharged at acidic pH, with a negative calculated logP. On a conventional C18 column with a high aqueous mobile phase there is little to retain it, so it appears early and is easily distorted by the sample diluent. Polar-embedded or mixed-mode phases are the usual fix.
Does the N-oxide need a specification?
If it is present above the reporting threshold, yes, and it is the entry most worth controlling, because it is the only clearly oxidative species in the list. Its level responds to peroxide impurities in excipients, to oxygen ingress and to storage temperature, all of which are formulation variables rather than synthesis variables.
Is a 500 mg dose high enough to change the thresholds?
Not here. At 500 mg a day, 1.0 mg corresponds to 0.20 percent, which is above the 0.10 percent identification threshold, so the percentage limit governs. The absolute limit only starts to bind above 1 g a day.

Related Substances and Reference Standards

References and Sources

  1. ICH, ICH Q3A(R2) Impurities in New Drug Substances: reporting threshold 0.05 percent, identification threshold 0.10 percent or 1.0 mg per day, qualification threshold 0.15 percent or 1.0 mg per day, whichever is lower, accessed 2026-11-04
  2. Journal of Colloid and Interface Science (2013), Surface-enhanced Raman scattering of picolinamide, nicotinamide and isonicotinamide: unusual carboxamide deprotonation under adsorption on silver nanoparticles (the three isomers bind metal surfaces through the deprotonated amide, with position-dependent shifts), accessed 2026-11-04
  3. ICH, ICH Q2(R2) Validation of Analytical Procedures: specificity, resolution between critical pairs, and the requirement to demonstrate that a method is selective for the analytes it claims, accessed 2026-11-04
  4. Chinese Pharmacopoeia Commission, Pharmacopoeia of the People's Republic of China, nicotinamide monograph and general chapters on related substances (monograph search portal), accessed 2026-11-04

This article was prepared by the CATO technical team. Regulatory, pharmacopoeial and published literature content cited above is attributed in the reference list. It is provided for technical exchange and search reference only and does not constitute a quality specification or regulatory advice. For any specific substance, the applicable test methods, limits and filing requirements are governed by the current regulations, pharmacopoeial monographs and official publications.

Product information on this site is provided for research search and selection reference only and is not a quality specification; technical data, purity and structural confirmation are governed by the shipped COA and our written confirmation. All products mentioned are for research use only, not for human or animal diagnostic or therapeutic use.